Indian pharma stocks are rebounding, driven by domestic investors after a period of Foreign Institutional Investor (FII) selling pressure. Uncertainty surrounding potential US tariffs, fueled by Trump’s statements and delays in the Bilateral Trade Agreement (BTA), had initially impacted the sector. While FIIs remain cautious, positive earnings reports and the defensive nature of domestic-oriented pharma businesses are attracting DII interest.
AI stocks: Midterm elections could threaten AI trade as data center backlash grows
Public opposition to US data centers and the November midterm elections could reshape AI infrastructure investment. Increased regulatory scrutiny, rising electricity costs and construction delays
October 23, 2026